Entera Bio Ltd.
Entera Bio develops oral tablet formulations of peptides and proteins for chronic diseases where injection-based therapies currently dominate.
Entera Bio Ltd is a Healthcare company operating in Biotechnology with a $72.9M market cap.
ENTX beat consensus EPS by 0.5% in Q1 FY2026, reported May 7, 2026.
4 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Extracted from Unknown source, 2026-06-21.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Spoken Alpha tracks ENTX's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 6/10 quarters with 50% positive reaction rate
SampleSpoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for ENTX.
$ curl https://api.spokenalpha.com/v1/companies/ENTXFAQ
Spoken Alpha indexes ENTX's earnings call transcripts at https://spokenalpha.com/companies/ENTX. Each call links to attributed speakers and parsed analyst Q&A. Entera Bio Ltd.'s own investor relations page is at https://investors.enterabio.com/.
Entera Bio Ltd. (ENTX) held its most recent earnings call on 2022-05-18, covering fiscal Q1 2022.
Entera Bio Ltd. (ENTX) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q1 FY2026 | 2026-05-07 | $-0.07 | $-0.15 | +53.3% | $0 | — | — | EODHD |
| Q4 FY2025 | 2026-03-26 | $-0.06 | $-0.11 | +45.5% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-13 | $0.07 | $-0.09 | +100.0% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-07 | $-0.06 | $-0.11 | +45.5% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-07 | $-0.06 | $-0.07 | +13.3% | $42.0K | — | — | EODHD |
| Q4 FY2024 | 2025-03-05 | $-0.06 | $-0.08 | +25.0% | $82.0K | — | — | EODHD |
| Q3 FY2024 | 2024-11-11 | $-0.08 | $-0.05 | -60.0% | $42.0K | — | — | EODHD |
| Q2 FY2024 | 2024-08-08 | $-0.06 | $-0.06 | 0.0% | $57.0K | — | — | EODHD |
| Q1 FY2024 | 2024-05-09 | $-0.05 | $-0.06 | +16.7% | $0 | — | — | EODHD |
| Q4 FY2023 | 2024-03-07 | $-0.07 | $-0.08 | +12.5% | $4.5M | — | — | EODHD |
| Q3 FY2023 | 2023-11-13 | $-0.07 | $-0.09 | +22.2% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-10 | $-0.14 | $-0.07 | -100.0% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-04 | $-0.08 | $-0.12 | +33.3% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-30 | $-0.10 | $-0.11 | +9.1% | $14.0K | — | — | EODHD |
| Q3 FY2022 | 2022-11-09 | $-0.11 | $-0.13 | +15.4% | $8.0K | — | — | EODHD |
| Q2 FY2022 | 2022-08-10 | $-0.11 | $-0.16 | +31.3% | $44.0K | — | — | EODHD |
| Q1 FY2022 | 2022-05-11 | $-0.13 | $-0.18 | +27.8% | $68.0K | — | — | EODHD |
| Q4 FY2021 | 2022-03-07 | $-0.21 | $-0.23 | +8.7% | $165.0K | — | — | EODHD |
| Q3 FY2021 | 2021-11-09 | $-0.09 | $-0.11 | +18.2% | $140.0K | — | — | EODHD |
| Q2 FY2021 | 2021-08-15 | $-0.21 | $-0.12 | -75.0% | $109.0K | — | — | EODHD |
Source: EODHD. ENTX reported actuals as published; sparse fields render as —.
Consistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2022 | $0.79 | $0.77 | +2.4% | -2.3% | -2.3% |
| Q4 FY2022 | $0.61 | $0.63 | -3.7% | +0.8% | +1.4% |
| Q3 FY2022 | $0.90 | $0.84 | +7.7% | -4.4% | -6.2% |
| Q2 FY2022 | $0.78 | $0.74 | +5.7% | +1.7% | +1.9% |
| Q1 FY2021 | $0.70 | $0.71 | -1.7% | -0.2% | +1.6% |
CFO since 2024 • 1/2 beats (50%) • last guidance cut Q3 FY2022
| Q4 FY2021 |
| $0.73 |
| $0.75 |
| -2.8% |
| +2.6% |
| +0.6% |
| Q3 FY2021 | $1.00 | $0.91 | +10.4% | +4.0% | +3.1% |
| Q2 FY2021 | $0.95 | $0.97 | -2.4% | -0.3% | -1.2% |
| Q1 FY2020 | $0.81 | $0.74 | +9.7% | +5.6% | +4.7% |
| Q4 FY2020 | $0.92 | $0.83 | +10.7% | -4.3% | -4.6% |